BACKGROUND:Percutaneous coronary intervention provides a high-risk condition for incidence of CIN even in patients with normal renal function. Pentoxifylline (PTX) with a variety of mechanisms may prevent CIN. MATERIALS AND METHODS:Between April 5, 2011, and February 20, 2012, all consecutive eligible patients referred for elective percutaneous coronary intervention were asked to participate in the study (n = 199). Eligibility was defined as the age between 18 and 65 years and baseline serum creatinine ≤ 132.6 μmol/l (1.5 mg/dl). The patients were randomly allocated to two groups either receiving saline or saline plus pentoxifylline 400 mg orally three times a day for 48 h. Serum creatinine was measured 24 h prior to the procedure and 48 h thereafter. The primary endpoint was occurrence of CIN defined as 25 % rise in serum creatinine 48 h after the procedure. RESULTS: The overall incidence of CIN was 6 % in this study (6.2 % in the PTX group versus 5.9 % in the hydration group, P = 0.92). Absolute rise in serum creatinine was not also significantly different between the two groups (P = 0.97). In hypertensive patients, however, the incidence of CIN was lower among those receiving PTX: 5 % in the PTX group versus 8.7 % in the hydration group. Nevertheless, this difference was not statistically significant (P = 0.68). CONCLUSION: Short-term prophylaxis with pentoxifylline added to optimal hydration does not seem to reduce the risk of CIN in patients with normal renal function undergoing PCI. Further clinical trials in patients with renal impairment are warranted to define its role.
RCT Entities:
BACKGROUND: Percutaneous coronary intervention provides a high-risk condition for incidence of CIN even in patients with normal renal function. Pentoxifylline (PTX) with a variety of mechanisms may prevent CIN. MATERIALS AND METHODS: Between April 5, 2011, and February 20, 2012, all consecutive eligible patients referred for elective percutaneous coronary intervention were asked to participate in the study (n = 199). Eligibility was defined as the age between 18 and 65 years and baseline serum creatinine ≤ 132.6 μmol/l (1.5 mg/dl). The patients were randomly allocated to two groups either receiving saline or saline plus pentoxifylline 400 mg orally three times a day for 48 h. Serumcreatinine was measured 24 h prior to the procedure and 48 h thereafter. The primary endpoint was occurrence of CIN defined as 25 % rise in serum creatinine 48 h after the procedure. RESULTS: The overall incidence of CIN was 6 % in this study (6.2 % in the PTX group versus 5.9 % in the hydration group, P = 0.92). Absolute rise in serum creatinine was not also significantly different between the two groups (P = 0.97). In hypertensivepatients, however, the incidence of CIN was lower among those receiving PTX: 5 % in the PTX group versus 8.7 % in the hydration group. Nevertheless, this difference was not statistically significant (P = 0.68). CONCLUSION: Short-term prophylaxis with pentoxifylline added to optimal hydration does not seem to reduce the risk of CIN in patients with normal renal function undergoing PCI. Further clinical trials in patients with renal impairment are warranted to define its role.
Authors: Javier Escobar; Javier Pereda; Alessandro Arduini; Juan Sandoval; Mari Luz Moreno; Salvador Pérez; Luis Sabater; Luis Aparisi; Norberto Cassinello; Juan Hidalgo; Leo A B Joosten; Máximo Vento; Gerardo López-Rodas; Juan Sastre Journal: Biochem Pharmacol Date: 2011-10-08 Impact factor: 5.858
Authors: Vincent E Friedewald; Stanley Goldfarb; Warren K Laskey; Peter A McCullough; William C Roberts Journal: Am J Cardiol Date: 2007-06-04 Impact factor: 2.778
Authors: Jose M Lopez-Novoa; Yaremi Quiros; Laura Vicente; Ana I Morales; Francisco J Lopez-Hernandez Journal: Kidney Int Date: 2010-09-22 Impact factor: 10.612
Authors: Somjot S Brar; Albert Yuh-Jer Shen; Michael B Jorgensen; Adam Kotlewski; Vicken J Aharonian; Natasha Desai; Michael Ree; Ahmed Ijaz Shah; Raoul J Burchette Journal: JAMA Date: 2008-09-03 Impact factor: 56.272
Authors: Mauro Maioli; Anna Toso; Mario Leoncini; Michela Gallopin; Delio Tedeschi; Carlo Micheletti; Francesco Bellandi Journal: J Am Coll Cardiol Date: 2008-08-19 Impact factor: 24.094
Authors: Judith Kooiman; Jean-Paul P M de Vries; Jan Van der Heyden; Yvo W J Sijpkens; Paul R M van Dijkman; Jan J Wever; Hans van Overhagen; Antonie C Vahl; Nico Aarts; Iris J A M Verberk-Jonkers; Harald F H Brulez; Jaap F Hamming; Aart J van der Molen; Suzanne C Cannegieter; Hein Putter; Wilbert B van den Hout; Inci Kilicsoy; Ton J Rabelink; Menno V Huisman Journal: PLoS One Date: 2018-02-08 Impact factor: 3.240